Research Article
Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment
Table 2
Longitudinal fluctuations in serum anti-EBNA-1 and anti-VCA IgG levels in relapsing remitting multiple sclerosis (RRMS) patients, considered as a whole, during 21 months of Natalizumab treatment.
| ||||||||||||||||||||||||||||||||||||
AU = arbitrary units; EBNA-1 = Epstein-Barr nuclear antigen-1; IQR = interquartile range; SD = standard deviation; = baseline; = the 3rd month; = the 6th month; = the 9th month; = the 12th month; = the 15th month; = the 18th month; = the 21st month; VCA = Epstein-Barr viral capsid antigen. |